Apnimed Announces $62.5 Million Series C Financing to Advance Development of Novel Pharmaceutical Treatments for Obstructive Sleep Apnea (OSA) and Related Sleep Disorders
Apnimed announced today that it has raised $62.5 million of committed capital in a Series C financing.
Apnimed will participate in 1×1 investor meetings at the 21st Needham Healthcare Conference taking place virtually April 11-14, 2022.
Apnimed will participate in the 32nd Annual Oppenheimer Conference taking place March 15-17, 2022 virtually.
Data from Apnimed’s Phase 2 study APC-004 will be featured in the company’s oral presentation at World Sleep 2022 in Rome, Italy on Monday, March 14.
Apnimed company management will participate in 1×1 investor meetings at the SVB Leerink Global Healthcare Conference.
Larry Miller, M.D., Chief Executive Officer, will present in a virtual format on Wednesday, January 12th at 5:30 p.m. ET.
Apnimed Announces Dosing of First Patient in Phase 2 MARIPOSA Confirmatory Trial of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea (OSA)
Apnimed announces the dosing of the first patient in the Phase 2b MARIPOSA study of AD109.
Apnimed Achieves Meaningful Results in Proof-of-Concept Crossover Study with Oral Therapeutic Candidates AD504 and AD182 for the Treatment of Obstructive Sleep Apnea
Apnimed announces positive results from a proof-of-concept crossover study in patients with OSA evaluating AD504 and AD182.
Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Treatment for the Disease
Apnimed today announced positive data across multiple endpoints from its Phase 2 randomized, double-blind, placebo-controlled, crossover clinical trial (Study APC-004) evaluating the efficacy and safety of AD109 as a treatment for patients with mild to moderate OSA.
Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment
Apnimed announced positive data across multiple endpoints from a Phase 2 randomized, double-blind, placebo-controlled, four-period, single-dose crossover factorial clinical trial (APC-003), and a 28-day open-label extension study, evaluating AD109 as a treatment in patients with mild to severe OSA.
GET APNIMED UPDATES